Advanced 3D cancer models for analyzing tumor-immune cell interaction and therapeutic response
Jeevanandan SP., Reidy E., Clegg J., Curvello R., Ryan AE., Loessner D.
Narrative Review, published in Mol Cancer (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Mol Cancer (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42157225
- PMCID
- PMC13188272
- DOI
- 10.1186/s12943-026-02681-y
Abstract (original English)
Immunotherapy is transforming the treatment of cancer by activating and directing a patient's own immune response to target tumor cells. In solid tumors, however, there has been limited success in sustaining anti-tumor immune responses. This is attributed to the intrinsic features of the tumor microenvironment, including the lack of infiltrating immune cells and varying expression of tumor antigens, forming an immunosuppressive landscape. Despite recent advances, we do not fully understand how the immune components of the tumor microenvironment are linked to ineffective treatment outcomes. Advanced 3D cancer models offer a platform to deconstruct tumor tissues and study disease progression and resistance to treatment, helping to uncover drivers of immune evasion in a physiologically relevant context. Here, we discuss aspects of the tumor immune microenvironment in selected solid tumors defined by distinct immunosuppressive features that dictate response to immunotherapy. We highlight how advanced 3D cancer models accelerate the development and screening of therapeutic strategies that target the immunosuppressive microenvironment.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.